Morgan Stanley: DEA Likely To Reclassify GW Pharma’s Cannabinoid Therapy For US Launch

gw

By Sunday night, the U.S. Drug Enforcement Administration is expected to reclassify GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s Epidiolex to allow medicinal use. This could open the therapy to a new and promising market.

Continue reading “Morgan Stanley: DEA Likely To Reclassify GW Pharma’s Cannabinoid Therapy For US Launch”